Prophylaxis in haemophilia: a double-blind controlled trial.
A double-blind controlled trial of prophylactic factor VIII therapy has been carried out on nine severe haemophiliacs at the Lord Mayor Treloar College. Infusions were given once weekly and calculated to give a post-infusion plasma concentration of at least 0.25 I.U./ml of factor VIII. This regime reduced the overall bleeding frequency by 15%. The bleeding frequency in the first 3 days post-infusion was reduced by 66%. A moderate overall reduction in morbidity was also achieved. It is calculated that to reduce the incidence of bleeding in severe haemophiliacs by 15% would require a 73% increased usage of therapeutic materials. More than twice this amount of material is likely to be needed to reduce the bleeding frequency of the same group by 66%.
D000293:Adolescent; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D006505:Hepatitis / Q000150:complications; D006801:Humans; D008297:Male; D009017:Morbidity; D013997:Time Factors
D005169:Factor VIII